ABOUT US
Passion For What We Do!
Altum Sequencing was founded with a clear purpose: to change how cancer is monitored. While oncology has advanced in treatment, detecting relapse and measuring response in real time remains one of the biggest clinical gaps.
We develop ultra-sensitive, tumor-informed liquid biopsy solutions powered by an AI-driven platform that enables clinicians and researchers to track cancer at the molecular level earlier, more precisely, and with real clinical impact.
Our Vision
To redefine cancer monitoring by making molecular information accessible, actionable, and timely, empowering clinicians to act earlier and giving patients more time.
Our Mission
To develop and scale ultra-sensitive ctDNA solutions that detect one tumour cell among one million healthy cells, enabling early relapse detection across multiple cancer types.
Where We Are
Headquartered in Madrid, Spain, at the heart of Southern Europe's leading biomedical and oncology research ecosystem.
Our Team
Built by the best in oncology and genomics
Our team combines deep clinical expertise in hematology and oncology with cutting-edge bioinformatics and molecular biology. Every member is committed to translating science into better patient outcomes.
Board Chair & Co-Founder
Joaquín Martínez MD, PhD
Head of Hematology at Hospital 12 de Octubre, Director of the Hematologic Tumors Program at CNIO, and Professor at UCM. Internationally recognized leader in MRD, biomarkers, and clinical trial strategy. Author of 400+ publications.
CEO
Marina Planas MBA
Entrepreneur and executive with experience scaling industrial and tech-driven companies. Leads Altum’s strategy, fundraising, and execution, building scalable, data-driven healthcare solutions.
Oncology Medical Director & Co-Founder
Luis Paz-Ares MD, PhD
Head of Medical Oncology at Hospital 12 de Octubre and leading figure in clinical oncology. Extensive experience in biomarkers, targeted therapies, and global clinical trials.
Hematology Medical Director & Co-Founder
Rosa Ayala MD, PhD
Head of the Molecular Biology Laboratory at Hospital 12 de Octubre. Expert in molecular diagnostics and assay validation, with strong clinical integration.
CTO
Jaume Ferré
Technology leader with experience scaling complex hardware/ software platforms. Leads Altum Atlas development, ensuring a robust and scalable tech infrastructure.
Head of Scientific Product
Isabel Espejo PhD
NGS expert in oncology with strong experience in assay development and translational research. Bridges clinical needs and product development to deliver scalable, clinically relevant solutions.
Head of Bioinformatics
Alejandro Martín
Leads development of scalable bioinformatics pipelines for ultra-sensitive sequencing. Focused on robust algorithms and clinical-grade data interpretation.
Head of Laboratory
Natalia Buenhache, PhD
Leads laboratory operations with expertise in clinical workflows and wet-lab standardization. Ensures reproducibility and scalability of lab processes.
Head of Regulatory Affairs
Arancha Sánchez PhD
Regulatory expert in liquid biopsy and NGS diagnostics with 14+ years of experience. Deep knowledge of U.S. and global approval pathways, including companion diagnostics.
Company Journey
Our journey building precision oncology
From a founding idea in Madrid to expansion — our milestones reflect the collective commitment of our team and partners.
Foundation
Altum Sequencing Founded
Three oncologists, Joaquin Martinez, Rosa Ayala, and Luis Paz-Ares, founded Altum with a clear mission: to close the gap in post-treatment cancer monitoring through ultra-sensitive ctDNA analysis.
2019
2020
Intellectual Property
Patent Family 2 — Priority Filing
MRD Detection Platform, covering targeted NGS with multi-biomarker monitoring and computational filtering algorithms. International PCT application filed, with national phases subsequently granted in Europe, Spain, US, China, Japan and Korea (valid until 2040).
Intellectual Property
Freedom-to-Operate — Patent Family 1
FTO granted for Patent Family 1 (MRD Quantification via NGS, priority Nov 2014, valid until 2034, granted in Europe, Spain and United States).
2021
2022
Clinical Validation
Clinical Validation in Hematologic Malignancies
EVOseq validated in CML and Ph+ ALL, detecting TKI resistance mutations in the ABL1 kinase domain with 92% sensitivity, 81.6% specificity and 100% applicability. Madrid laboratory received ISO 15189 accreditation (Sánchez R. et al., Scientific Reports, 2022).
Growth
Expansion to Solid Tumors
Platform expanded to solid tumor indications across colorectal, breast, lung and other cancer types.
2023
2024
MILESTONE
6,000+ Samples Analyzed
Over 6,000 clinical and research samples processed across validated settings. ESMO and ASH presentations confirmed.
TEAM
The Team is Growing
The team expanded to 20+ members across clinical science, bioinformatics, and regulatory affairs.
2025
Our Location
At the heart of European biomedical science.
We are headquartered in Spain, one of Europe's leading biomedical research hubs, home to world-class hospitals, research institutes, and a thriving life sciences ecosystem. Our laboratory operates worldwide.
Address
Av. Gregorio Peces Barba 1, 28919 Leganés, Madrid
Service Area
Clinical services and logistics available worldwide.
